Résumé
Aim: To determine which of the CDK4/6 inhibitors is the optimal treatment in metastatic luminal breast cancer. Materials & methods: A network meta-analysis using the frequentist approach and generalized pairwise modeling was computed. Results: The associations of aromatase inhibitor with ribociclib, palbociclib and abemaciclib were similar in efficacy. Palbociclib-based regimen was associated with significantly lower treatment discontinuation rates compared with the other approved drugs in this indication. Conclusion: In the absence of direct comparative evidence, the results of this network meta-analysis represent the best available evidence for decision making in the first-line treatment of metastatic luminal breast cancer.
langue originale | Anglais |
---|---|
Pages (de - à) | 891-895 |
Nombre de pages | 5 |
journal | Future Oncology |
Volume | 14 |
Numéro de publication | 9 |
Les DOIs | |
état | Publié - 1 avr. 2018 |
Modification externe | Oui |